Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer

Authors

Katherine C Fuh, Washington University School of Medicine in St. Louis
Michael A Bookman, Kaiser Permanente
Joyce F Liu, Dana-Farber Cancer Institute
Robert L Coleman, US Oncology Network
Thomas J Herzog, University of Cincinnati
Premal H Thaker, Washington University School of Medicine in St. Louis
Bradley J Monk, University of Arizona
Randy Anderson, Aravive, Inc.
Gail McIntyre, Aravive, Inc.
Reshma Rangwala, Aravive, Inc.
Kathleen N Moore, University of Oklahoma

Journal

Gynecologic Oncology

Publication Date

11-1-2021

Volume

163

Issue

2

First Page

254

Last Page

261

Document Type

Open Access Publication

DOI

10.1016/j.ygyno.2021.08.020

Rights and Permissions

Fuh KC, Bookman MA, Liu JF, Coleman RL, Herzog TJ, Thaker PH, Monk BJ, Anderson R, McIntyre G, Rangwala R, Moore KN. Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. Gynecol Oncol. 2021 Nov;163(2):254-261. doi: 10.1016/j.ygyno.2021.08.020. © 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Fuh, Katherine C; Bookman, Michael A; Liu, Joyce F; Coleman, Robert L; Herzog, Thomas J; Thaker, Premal H; Monk, Bradley J; Anderson, Randy; McIntyre, Gail; Rangwala, Reshma; and Moore, Kathleen N, "Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer." Gynecologic Oncology. 163, 2. 254 - 261. (2021).
https://digitalcommons.wustl.edu/oa_4/3475

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.